Citigroup maintains neutral on BridgeBio Pharma, cuts price target

Citigroup analyst Eric Joseph maintains a Neutral rating on BridgeBio Pharma. Price target lowered from $94 to $91. Rating status remains unchanged despite valuation adjustment.

BridgeBio Pharma grants 57,853 RSUs to 32 new employees

BridgeBio Pharma granted 57,853 restricted stock units to 32 new employees. Grants approved on October 14, 2026, under Nasdaq Listing Rule 5635(c)(4). Initial 25% of shares vest on November 16, 2027, with remainder vesting quarterly. Awards issued pursuant to the company's equity incentive plan amended in 2023.

BridgeBio encaleret shows 100% symptom improvement in Phase 3 ADH1 trial

100% of encaleret-treated patients reported improvement in at least one ADH1 symptom versus 46% on standard care. Encaleret increased bone turnover by recovering endogenous PTH secretion in ADH1 patients. FDA granted Priority Review for encaleret NDA with PDUFA target action date of May 8, 2027. First participant dosed in RECLAIM-HP registrational Phase 3 study for chronic hypoparathyroidism.

Acoramidis linked to 18% lower risk vs tafamidis in real-world study

Independent Epic COSMOS analysis shows acoramidis associated with 18% lower risk of composite adverse outcomes versus tafamidis. Acoramidis linked to 27% lower risk of cardiovascular and heart failure hospitalizations compared to tafamidis. Findings replicate earlier claims-based data showing 34% reduction in clinical worsening events. ATTRibute-CM data reveals mortality risk doubles after one and quadruples after two cardiovascular hospitalizations.

BridgeBio presents new cardiac data for BBP-418 at WMS congress

BBP-418 normalized troponin I levels in 100% of treated patients with elevated baselines versus 40% in placebo. Mean decline in troponin I was significantly greater in the treatment group (LS mean difference -17.8 ng/L). 54% of BBP-418-treated individuals had stable or improved LVEF at Month 12 compared to 25% in placebo. Glycosylated alpha-dystroglycan levels increased to asymptomatic carrier levels by Month 3 and sustained through Month 12. Data presented at the World Muscle Society Congress supports potential disease modification.

BridgeBio real-world data shows acoramidis cuts worsening risk 34%

Acoramidis showed a 34% reduction in composite clinical worsening risk versus tafamidis. Diuretic intensification risk fell 43% in patients treated with acoramidis. Study analyzed 618 newly treated ATTR-CM patients using U.S. claims data. Fewer acoramidis patients switched therapies (4.6%) compared to tafamidis (7.7%).